BIAKESO@EC2611A

JPMorgan Maintains Positive Rating on CanAngela Biopharma

Chinese Innovative Pharmaceutical Companies Excel at 2026 ASCO Conference, Boosting Global Influence

First Shanghai Securities and CMB International Securities Maintain Buy Rating for Akeso

CanSino Biologics' AK112 Beats Merck's Keytruda, Achieves Systemic Transformation in Two Years

Guo Jin Securities Predicts Kangke Biotech's 2026 Net Profit to Grow Significantly

CICC and China International Securities Maintain Buy Rating and Set Target Price for Kangao Biologics

Canbiopharm Revenue Increases 43.9% in 2025, IVO-3001 FDA Application Accepted

CanAngen's Revenue Grew by 43.9% to 3.056 Billion Yuan in 2025

AKESO released FY2025 Q3 earnings on March 26, 2026 (BJT) with actual revenue of HKD 898.99 M and EPS of HKD -0.3259

AKESO released FY2025 9-month earnings on March 26 (BJT), actual revenue HKD 2.427 B, actual EPS HKD -1.0188

Kangkang Biotech Inc. Revenue Reaches 3.056 Billion Yuan in 2025, Loss Widens to 1.141 Billion Yuan

AKESO released FY2025 earnings on March 26 During-Market (BJT), actual revenue HKD 3.34 B (forecast HKD 3.655 B), actual EPS HKD -1.3473 (forecast HKD -0.3407)

AKESO released FY2025 Q4 earnings on March 26 During-Market (BJT), actual revenue HKD 914.5 M, actual EPS HKD -0.3315

AKESO to release FY2025 earnings report on March 26 During-Market (BJT), forecast revenue HKD 3.726 B, EPS HKD -0.3479

CanAngen's AK150 Receives Clinical Trial Approval

Nomura Adjusts Kanghong Biotech Revenue Forecast and Target Price

CanSino and Inovio Partner to Evaluate Efficacy in Glioblastoma Treatment

NMPA Approves Kangkang Biotech's AK139 to Enter Phase II Clinical Trials for 7 Indications

Kangkang Biologics Grants JinChuan Pharmaceutical Exclusive Commercialization Rights to Enoximab

CanSino Biologics' PD-1/VEGF Bi-specific Antibody Ivolimab Receives FDA Acceptance

JOLIMARK

TIMES UNI GP

APEX ACE HLDG

VPOWER GROUP

GW TIANDI

FUJING HOLDINGS

TEAMWAY INTL GP

SFSY NEW MAT

FDB HOLDINGS

KEEN OCEAN

01801

603259

09926

02359

520880

159316

Hong Kong's biotech sector saw significant gains as Innovent Biologicsrose over 10%, Akesoincreased by more than 6%, and WuXi AppTecclimbed over 5%. According to Jin10, the innovation-driven rally highlights investor confidence in the sector's growth potential.

CoinLive

INNOVENT BIO

WuXi AppTec

AKESO

WUXI APPTEC

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

STOCKS | Hong Kong Biotech Stocks Surge with Innovent Biologics Leading Gains

00992

01347

02600

02476

03993

09980

06869

00288

03750

LENOVO GROUP(00992) rose 15.49%, with a trading turnover 9.9 Billion HKD, and a year-to-date rose 96.4%. HUA HONG SEMI(01347) rose 10.45%, with a trading turnover 11.6 Billion HKD, and a year-to-date rose 93.4%. EASTROC(09980) fell 8.92%, with a trading turnover 88.0 Million HKD, and a year-to-date fell 44.2%. YOFC(06869) fell 6.15%, with a trading turnover 3.6 Billion HKD, and a year-to-date rose 313.2%.

Top Gainers&Losers

LENOVO GROUP

HUA HONG SEMI

CHALCO

CMOC

EASTROC

YOFC

WH GROUP

CATL

Top 5 HK Stock Gainers/Losers (>100B) (5.26)

01530

As of May 26, 2026, Hwabao WP Hang Seng SCHK Innovative Drug ETF (520880) fell by 1.57%, closing at CNY 0.438, hitting a historical low. This ETF closely tracks the Hang Seng SCHK Innovative Drug Select Index, with the latest size reaching CNY 2.697 billion and shares totaling 5.976 billion. In the past week, it attracted CNY 99.7502 million. Among the index constituents, AKESO and 3SBIO both fell by over 3%

同壁财经

3SBIO

ZAI LAB

Zai Lab

REMEGEN

RemeGen

SBP GROUP

Sunshine Guojian Pharmaceutical

Innovative drugs are sluggish, Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880) hits a new historical low! AKESO and 3SBIO drop over 3%

02513

00100

01888

02423

06030

01776

KNOWLEDGE ATLAS(02513) rose 26.93%, with a trading turnover 3.6 Billion HKD, and a year-to-date rose 1003.3%. LENOVO GROUP(00992) rose 19.77%, with a trading turnover 8.3 Billion HKD, and a year-to-date rose 70.1%. BEKE-W(02423) fell 5.26%, with a trading turnover 875.3 Million HKD, and a year-to-date rose 5.1%. EASTROC(09980) fell 3.03%, with a trading turnover 14.8 Million HKD, and a year-to-date fell 38.7%.

KNOWLEDGE ATLAS

MINIMAX-W

KB LAMINATES

BEKE-W

CITIC SEC

GF SEC

Top 5 HK Stock Gainers/Losers (>100B) (5.22)

On May 21, the three major indices of the Hong Kong stock market opened high and then fell, with the Hang Seng Index dropping 1.03% and the Hang Seng Tech Index plunging 2.15%. The technology and internet sectors were generally under pressure, with significant declines in large tech stocks. Pharmaceutical stocks were partially active, with Asymchem and AKESO rising against the trend. International gold prices weakened, and market analysis suggests that the Hong Kong stock market is currently in a bottoming phase, with future opportunities expected to focus on the AI industry chain, semiconductors, and leading internet companies

- On May 21, Hong Kong's major indices opened high but ended lower, with the Hang Seng Index falling by 1.03%.  
- Large tech stocks experienced significant declines, such as Bilibili dropping nearly 8%, while some pharmaceutical stocks gained, like Kelaiying.  
- Analysts suggest that the market is in a consolidation phase, with structural opportunities expected in the AI industry and semiconductor sectors amid pressures on gold prices due to the Federal Reserve's stance on interest rates.

Asymchem

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Huaan Hang Seng Biotech ETF

MEITUAN

Hang Seng Index

Hang Seng TECH Index

Bilibili

BILIBILI-W

Alibaba

BABA-W

TENCENT

Tencent

WELLCELL HOLD

ChinaAMC Hang Seng Technology ETF(QDII)

ChinaAMC CNI HK Connect Technology ETF

ChinaAMC Hang Seng ETF

BABA-WR

Alibaba HK SDR 5to1

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

The Hang Seng Index and the Tech Index both fell, focusing on the layout opportunities in the Hong Kong stock sector

09927

00501

09868

06082

09888

01024

06613

SERES(09927) rose 5.09%, with a trading turnover 218.1 Million HKD, and a year-to-date fell 33.9%. OMNIVISION(00501) rose 5%, with a trading turnover 239.8 Million HKD, and a year-to-date fell 9.7%. BIREN TECH(06082) fell 7.69%, with a trading turnover 339.2 Million HKD, and a year-to-date rose 138.8%. YOFC(06869) fell 6.84%, with a trading turnover 3.4 Billion HKD, and a year-to-date rose 316.2%.

- The Hang Seng Index fell by 1.03%, with a year-to-date decline of 1%.  
- The Hang Seng Tech Index decreased by 2.15%, accumulating a 13.5% loss for the year.  
- Notable movements include Sai Liu Si rising by 5.09% despite a 33.9% year-to-date drop, while Wall Group and Biran Technology saw gains and losses, respectively, throughout the year.

SERES

OMNIVISION

XPENG-W

BIREN TECH

BIDU-SW

KUAISHOU-W

Lens

Top 5 HK Stock Gainers/Losers (>100B) (5.21)

As of May 21, 2026, the Hwabao (520880) Hang Seng SCHK Innovative Drug ETF rose by 1.81%, with the latest price reported at 0.450 yuan. Funds have been continuously increased for 7 days, with a total of 392 million yuan raised in the past week. This ETF closely tracks the Hang Seng SCHK Innovative Drug Select Index, with the latest scale reaching 2.665 billion yuan and a total of 5.982 billion shares

Beigene

BEONE MEDICINES

BeOne Medicines

SKB BIO

Bottoming out and rebounding! AKESO surged 5%, and Hwabao WP Hang Seng SCHK Innovative Drug ETF (520880) rose 1.58%! Funds have increased positions for 7 consecutive days

03986

02015

01209

00175

01109

KNOWLEDGE ATLAS(02513) rose 9.33%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 878.5%. VGT(02476) rose 8.47%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 75.7%. LI AUTO-W(02015) fell 14.15%, with a trading turnover 3.6 Billion HKD, and a year-to-date rose 0.1%. CHINA RES MIXC(01209) fell 6.19%, with a trading turnover 346.3 Million HKD, and a year-to-date rose 6.7%.

- The Hang Seng Index decreased by 1.11%, with a year-to-date increase of 0.2%.  
- The Hang Seng Tech Index fell by 1.95%, reflecting a year-to-date decline of 12.2%.  
- Notable stock movements include Zhizhu's 9.33% increase and an 878.5% cumulative rise for the year, alongside Lixiang Auto's 14.15% drop with minimal year-to-date growth.

GIGADEVICE

LI AUTO-W

CHINA RES MIXC

GEELY AUTO

CHINA RES LAND

Top 5 HK Stock Gainers/Losers (>100B) (5.18)

01681

06160

CONSUN PHARMA has recently shown a steady upward trend, with an increase of approximately 12.27%. The MACD daily bullish signal is gradually being established, with the fast and slow lines crossing above the zero axis, which usually indicates that the medium-term trend is transitioning from a consolidation phase to an upward breakout. The trading volume is about HKD 72.39 million, which, although not a large absolute amount, has significantly increased compared to the stock's historical average daily volume, indicating a rise in capital participation. The stock price is steadily rising, and the short-term moving averages are beginning to turn upward, forming an initial bullish arrangement. On the news front, the overall recovery trend in the pharmaceutical sector is evident. The Hong Kong stock biopharmaceutical index has stabilized and rebounded, with AKESO rising over 4% on the day and BEONE MEDICINES increasing nearly 3%, showing clear signs of capital returning to the sector. As a leader in the traditional Chinese medicine nephrology field, CONSUN PHARMA has a stable product matrix and excellent cash flow performance, making it a defensive yet flexible choice in the rotation of the pharmaceutical sector. Additionally, the domestic medical insurance policy's supportive stance towards traditional Chinese medicine remains unchanged, and the impact of centralized procurement on exclusive varieties is limited. The company's fundamentals are relatively certain, attracting some funds seeking stable returns. From a technical perspective, the current stock price is operating above the 5-day and 10-day moving averages, with both moving averages trending upward and maintaining a moderate distance, forming a step-like support. If today's trading volume remains above HKD 70 million and holds above the 5-day moving average, the upward trend is expected to continue. Attention should be paid to the previous high-pressure zone above, as a breakthrough may open up new upward space. The correlation between the Hong Kong pharmaceutical sector and the A-share market is worth noting, as the A-share market has also been active in the innovative drug sector recently

Technical Forecast

CONSUN PHARMA

Pre-market trend | CONSUN PHARMA (1681.HK) 5/6 moderately increased with volume, is capital flowing back into the pharmaceutical sector?

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

WUXI BIO

WuXi Biologics

FI2 CSOP HSI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

HORIZONROBOT-W

ZA ONLINE

BITFIRE GROUP

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

BIAKESO@EC2611A(29499.HK)

STOCKS | Hong Kong Biotech Stocks Surge with Innovent Biologics Leading Gains

Top 5 HK Stock Gainers/Losers (>100B) (5.26)

Innovative drugs are sluggish, Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880) hits a new historical low! AKESO and 3SBIO drop over 3%

Top 5 HK Stock Gainers/Losers (>100B) (5.22)

The Hang Seng Index and the Tech Index both fell, focusing on the layout opportunities in the Hong Kong stock sector